MiR-30a的下调与肺癌预后不良相关。
Downregulation of MiR-30a is Associated with Poor Prognosis in Lung Cancer.
作者信息
Tang Ruixue, Liang Lu, Luo Dianzhong, Feng Zhenbo, Huang Qiuxia, He Rongquan, Gan Tingqing, Yang Lihua, Chen Gang
机构信息
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang, China (mainland).
出版信息
Med Sci Monit. 2015 Aug 25;21:2514-20. doi: 10.12659/MSM.894372.
BACKGROUND
Recent reports have suggested that miR-30a plays a tumor-suppressive role in various cancers. However, miR-30a has not been completely studied in non-small lung cancer (NSCLC). Thus, the aim of the present study was to clarify the association between the expression of miR-30a and the clinicopathological features in NSCLC patients.
MATERIAL AND METHODS
Total RNA of miR-30a was extracted from 125 pairs of NSCLC patients (male 75, female 50) and their matching normal tissues. The miR-30a level was detected by using quantitative real-time polymerase chain reaction (qRT-PCR). Simultaneously, the 2-ΔCq method was used to calculate the correlation between miR-30a expression and the clinicopathological parameters and prognosis of NSCLC patients.
RESULTS
MiR-30a expression was significantly down-regulated in NSCLC tissues (4.0696±2.4178) compared to their non-tumor lung tissues (7.4530±3.0561, P<0.001). Level of miR-30a was negatively correlated to tumor size (r=-0.197, P=0.028), lymphatic metastasis (r=-0.312, P<0.001), clinical TNM stage (r=-0.299, P=0.001), pathological grading (I/II vs. III, r=-0.224, P=0.001), and histological classification (r=-0.299, P=0.001). Survival time was 3.23±2.18 months in the low miR-30a expression group, remarkably shorter than that of the high expression group (20.72±11.63 months, P<0.001).
CONCLUSIONS
MiR-30a may be regarded as a tumor suppressor in NSCLC, and it could become a prognostic marker and potential therapeutic target for NSCLC.
背景
最近的报道表明，miR-30a在多种癌症中发挥肿瘤抑制作用。然而，miR-30a在非小细胞肺癌（NSCLC）中的研究尚未完全明确。因此，本研究的目的是阐明miR-30a的表达与NSCLC患者临床病理特征之间的关联。
材料与方法
从125对NSCLC患者（男性75例，女性50例）及其配对的正常组织中提取miR-30a的总RNA。采用定量实时聚合酶链反应（qRT-PCR）检测miR-30a水平。同时，使用2-ΔCq法计算miR-30a表达与NSCLC患者临床病理参数及预后的相关性。
结果
与非肿瘤肺组织（7.4530±3.0561，P<0.001）相比，NSCLC组织中miR-30a表达显著下调（4.0696±2.4178）。miR-30a水平与肿瘤大小（r=-0.197，P=0.028）、淋巴转移（r=-0.312，P<0.001）、临床TNM分期（r=-0.299，P=0.001）、病理分级（I/II级与III级，r=-0.224，P=0.001）及组织学分类（r=-0.299，P=0.001）呈负相关。低miR-30a表达组的生存时间为3.23±2.18个月，明显短于高表达组（20.72±11.63个月，P<0.001）。
结论
miR-30a可能被视为NSCLC中的肿瘤抑制因子，并且它可能成为NSCLC的预后标志物和潜在治疗靶点。
Zotero 插件